Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Here, we describe the surprising residual capability of the Rb pathway to negatively regulate proliferation and tumorigenesis in a SV40 large T antigen (Tag)-driven mouse model of pancreatic islet carcinogenesis. Heterogeneous Tag expression during all progression stages suggested that a threshold level of the T antigen oncoprotein might be deterministic for beta-cell hyperproliferation and led us to hypothesize that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Moreover, genomic profiling of these tumors by array CGH pointed to regions of loss on chromosomes 6 and 14, where the Rb pathway inhibitor p27 and Rb itself, respectively, reside. Indeed, genetic ablation of the p27(Kip1) or Rb genes accentuated Tag-induced tumorigenesis, with loss of Rb in particular broadly enhancing multiple parameters of tumorigenesis including the frequency and growth rates of premalignant lesions, of nascent solid tumors, and of invasive carcinomas. The data indicate that attenuation rather than complete inactivation of Rb tumor suppressor gene function, in the context of p53 inhibition, is sufficient to initiate tumorigenesis in this model of islet cell cancer, with the demonstrable possibility that subsequent losses of Rb or its regulators can enhance malignant progression. The results may be relevant to human papillomavirus (HPV)-induced cervical neoplasias where E7 oncogene expression levels or activity (in the case of intermediate/low-risk HPV subtypes) incompletely inhibits Rb tumor suppressor functions, as well as to other neoplasias where initiating oncogenic or tumor suppressor events reduce but do not abrogate Rb function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The senescence phenotype is dependent on the p16-RB pathway, thus unlike the aforementioned Tag-driven hepatoma model, the residual RB activity seems to be sufficient for senescence induction in this model 129”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [129]
In the citing paper
“Although Tag binds both RB and p53, it attenuates, rather than fully inactivates, their activity, thus their residual activities allow the RIP-Tag2 mice to exhibit progressive tumorigenesis with only a small portion of islets developing invasive pancreatic cancer 127,129”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [129]
Citations
Cites
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · cited 1×
“…to tumorigenesis in the context of loss of Rb, as shown by the fact that Rb germline knockout heterozygote mice also develop pituitary tumors (Jacks et al., 1992) and by the high incidence of pituitary tumors in familial retinoblastoma mutations, clinically called trilateral retinoblastoma…”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Self-citationHanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Marino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Beta-cell adaptation and decompensation during the progression of diabetes
Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S., & Sharma, A. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s154 · Cited by 462 · cited 1×
“…Smith and D Hanahan, unpublished results); second, the fact that proliferating b cells have been shown to downmodulate insulin gene transcription (Weir et al., 2001) and similarly may decrease insulin promoter-driven Tag expression; and third, the possibility of cell-to-cell variations in…”
BackgroundA second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis
Christofori, G., Naik, P., & Hanahan, D. (1994) · Nature · doi:10.1038/369414a0 · Cited by 390 · cited 2×
“In addition, the initial proliferative switch that initiates this pathway to islet carcinomas involves the focal activation of expression of IGF-2, which acts initially as a survival factor (Christofori et al., 1994).”
BackgroundSelf-citationInoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380 · cited 1×
“BrdU, TUNEL staining and H&E grading were performed as described previously (Inoue et al., 2002; Lopez and Hanahan 2002).”
MethodSelf-citationGenome scanning with array CGH delineates regional alterations in mouse islet carcinomas
Hodgson, G., Hager, J. H., Volik, S., Hariono, S., Wernick, M., Moore, D., Albertson, D. G., Pinkel, D., Collins, C., Hanahan, D., et al. (2001) · Nature Genetics · doi:10.1038/ng771 · Cited by 294
Self-citation
Research works printed but not linked: 1
- Giannoudis A and Herrington CS . (2000). Cancer, 89, 1300–1307. · doi:10.1002/1097-0142(20000915)89:6<1300::aid-cncr15>3.0.co;2-u
Cited by
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
Inside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K.-K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007) · Nature · doi:10.1038/nature05886 · Cited by 377
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., Libutti, S. K., Nakakura, E. K., Golub, T. R., & Hanahan, D. (2009) · Genes & Development · doi:10.1101/gad.1820109 · Cited by 260
Self-citationIntrinsic Regulators of Pancreatic β-Cell Proliferation
Heit, J. J., Karnik, S. K., & Kim, S. K. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104425 · Cited by 165
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 147
Willimsky, G., Czéh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., & Blankenstein, T. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072016 · Cited by 111
The supply chain of human pancreatic β cell lines
Scharfmann, R., Staels, W., & Albagli, O. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129484 · Cited by 60
T antigen transgenic mouse models
Robles, M. T. S., & Pipas, J. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.02.002 · Cited by 40
“In fact, genetic ablation of the pRb gene (or its regulator p27Kip1) accentuates T antigen-induced tumorigenesis, enhancing the frequency and growth rates of premalignant lesions, solid tumors, and invasive carcinomas [50].”
InfluentialLack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice
Loffler, K. A., Biondi, C., Gartside, M. G., Serewko-Auret, M. M., Duncan, R., Tonks, I. D., Mould, A. W., Waring, P., Muller, H. K., Kay, G. F., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210163 · Cited by 40
“We did not find an increase of islet adenomas in the Men1þ / ; Rb1DX2/þ animals compared to the Men1þ / ;Rb1þ /þ animals (5 versus 15%, respectively), in contrast to the effect of simultaneous loss of Rb1 and p53 (Williams et al., 1994; Casanovas et al., 2005).”
ResultG1 arrest and differentiation can occur independently of Rb family function
Wirt, S. E., Adler, A. S., Gebala, V., Weimann, J. M., Schaffer, B. E., Saddic, L., Viatour, P., Vogel, H. S., Chang, H. Y., Meissner, A., et al. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.201003048 · Cited by 37
“One limitation of experiments with these viral oncoproteins is the extent to which they inhibit Rb family members (e.g., Casanovas et al., 2005).”
BackgroundNew drug development in digestive neuroendocrine tumors
Durán, I., Salazar, R., Casanovas, O., Arrazubi, V., Vilar, E., Siu, L. L., Yao, J. C., & Tabernero, J. M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm009 · Cited by 36
Self-citationA mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen
ter Brugge, P. J., Ta, V. B. T., de Bruijn, M. J. W., Keijzers, G., Maas, A., van Gent, D. C., & Hendriks, R. W. (2009) · Blood · doi:10.1182/blood-2009-01-198937 · Cited by 43
Nolan-Stevaux, O., Truitt, M. C., Pahler, J. C., Olson, P., Guinto, C., Lee, D. C., & Hanahan, D. (2010) · Genes & Cancer · doi:10.1177/1947601909358722 · Cited by 31
Self-citationPrada, E. T. A., & Auernhammer, C. J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0286 · Cited by 33
Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors
Buicko, J. L., Finnerty, B. M., Zhang, T., Kim, B. J., Fahey, T. J., & Du, Y. N. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.06.02 · Cited by 32
“In this model, the rat insulin promoter (RIP) drives the expression of SV40 T antigen (Tag), providing the driving force for tumor initiation by inhibiting two tumor suppressors, p53 (54) and Rb (55).”
BackgroundChen, M., Rahman, L., Voeller, D. M., Kastanos, E. K., Yang, S. X., Feigenbaum, L., Allegra, C. J., Kaye, F. J., Steeg, P. S., & Zajac‐Kaye, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210273 · Cited by 27
“In addition, even the transgenic expression of the oncogenic SV40 large-T antigen showed a latency period, which was accelerated by cross-breeding mice with Rb and p53 null alleles (Casanovas et al., 2005).”
BackgroundModels of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions
Detjen, K. M., Hammerich, L., Özdirik, B., Demir, M., Wiedenmann, B., Tacke, F., Jann, H., & Roderburg, C. (2020) · Neuroendocrinology · doi:10.1159/000509864 · Cited by 23
Current status and future prospects for anti-angiogenic therapies in cancer
Staton, C. A., Brown, N. J., & Reed, M. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903196737 · Cited by 26
“This theory has been tested in RIP-Tag mice where treatment of early stage pancreatic tumours with an inhibitor of VEGF-R2 resulted in suppression of tumour growth, whereas there were minimal effects on the growth of advanced pancreatic tumours [155].”
MethodResultAliya, S., Farani, M. R., Kim, E., Kim, S., Gupta, V. K., Kumar, K., & Huh, Y. S. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115862 · Cited by 18
Zheng, H., Nakamura, T., Yang, Z., Nakanishi, Y., Tabuchi, Y., Uchiyama, A., Takahashi, H., & Takano, Y. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0599-z · Cited by 18
“…mice expressing the SV40 T-antigen could develop colon carcinoma (Gum et al. 2004), thymic carcinoma (Park et al. 1996), pancreatic islet tumor (Casanovas et al. 2005; Shen et al. 2007), hepatocellular and biliary cell tumor (Enomoto et al. 1998), mammary tumor (Shibata et al. 1999), and brain…”
BackgroundOf mice without pockets: mouse models to study the function of Rb family proteins
Vidal, A., Carneiro, C., & Zalvide, J. B. (2007) · Frontiers in bioscience · doi:10.2741/2403 · Cited by 15
Bakshi, H. A., Hakkim, F. L., Ravesh, Z., Ansari, P., Hannan, J. M. A., Hashimoto, R., Takayama, K., Farzand, R., Nasef, M. M., Mensah, A., et al. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354221096766 · Cited by 10
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms
Gaspar, T. B., Lopes, J. M., Soares, P., & Vinagre, J. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0166 · Cited by 5
Albagli, O., Maugein, A., Huijbregts, L., Bredel, D., Carlier, G., Martin, P., & Scharfmann, R. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0531-9 · Cited by 5
“Accordingly, Rb knock-out promotes proliferation and accelerates tumorigenesis in this experimental setting [25].”
BackgroundConditional deletion of RB1 in the Tie2 lineage leads to aortic valve regurgitation
Freytsis, M., Baugh, L. M., Liu, Z., Georgakoudi, I., Hinds, P. W., Black, L. D., & Huggins, G. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190623 · Cited by 4
Shen, Q., Sun, Q., Wei, X., Dong, J., Zhang, R., Wu, P., Jin, Y., Feng, J., Hou-da, L., & Hu, Y. (2007) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.104.14 · Cited by 4
The RB gene family controls the maturation state of the EndoC-βH2 human pancreatic β-cells
Maugein, A., Diedisheim, M., Bailly, K., Scharfmann, R., & Albagli, O. (2020) · Differentiation · doi:10.1016/j.diff.2020.02.001 · Cited by 3
Osherovich, L. Z. (2008) · Science-Business eXchange · doi:10.1038/scibx.2008.494
Role of Pre-B Cell Receptor Signaling Molecules in B Cell Differentiation and Tumor Suppression
Tạ, T. B. (2005) · RePub (Erasmus University Rotterdam)
Metadata
- Authors
- Casanovas, O., Hager, J. H., Chun, M. G. H., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Hanahan, Douglas
- Venue
- Oncogene
- Published
- 2005-06-27
- Volume
- 24
- Issue
- 44
- Pages
- 6597-6604
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2010314404
- Cited by
- 31
- References
- 26
- Citations by year
- 2023: 1 · 2022: 2 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 1 · 2014: 1 · 2013: 1
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- p53 inactivation, SV40 large T antigen, p27, malignant progression, HPV E7 oncogene, cervical neoplasia
- MeSH terms
- Animals, Humans, Immunohistochemistry, Islets of Langerhans, Mice, Transgenic, Pancreatic Neoplasms, Genes, Retinoblastoma, Mice, Knockout, Cell Cycle Proteins, Tumor Suppressor Proteins, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.